Comparative effectiveness of two lipid emulsions in preventing retinopathy of prematurity in preterm infants requiring parenteral nutrition

Mª José Cabañas Poy; José Bruno Montoro Ronsano; Félix Castillo Salinas; Nieves Martín-Begué; Susana Clemente Bautista; Mª Queralt Gorgas Torner

doi:10.1016/j.farma.2023.10.005

Comparative effectiveness of two lipid emulsions in preventing retinopathy of prematurity in preterm infants requiring parenteral nutrition

Farm Hosp. 2024 Mar 30:S1130-6343(23)00901-7. doi: 10.1016/j.farma.2023.10.005. Online ahead of print.

[Article in English, Spanish]

Authors

Mª José Cabañas Poy¹, José Bruno Montoro Ronsano², Félix Castillo Salinas³, Nieves Martín-Begué⁴, Susana Clemente Bautista², Mª Queralt Gorgas Torner²

Affiliations

¹ Servicio de Farmacia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address: mjosep.cabanas@vallhebron.cat.
² Servicio de Farmacia, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
³ Servicio de Neonatología, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
⁴ Unidad de Oftalmología Pediátrica, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

PMID: 38556369
DOI: 10.1016/j.farma.2023.10.005

Abstract

Objectives: The main aim was to compare the effects of 2 parenteral lipid emulsions on retinopathy of prematurity (ROP) incidence, severity, and need for treatment. Secondary aim was to compare the effect on weight gain in the first 6 weeks of life.

Methods: Single-center, observational, retrospective study analyzing preterm infants with a gestational age (GA) <31 weeks and a birth weight <1251 g born between April 2015 and December 2018. The infants' medical records were reviewed to collect clinical data. Parenteral nutrition (PN) details were obtained from the hospital pharmacy database.

Results: In total, 180 patients were included: 90 received ClinOleic® and 90 received SMOFlipid®. No significant differences were observed for the incidence of ROP (40% in ClinOleic® group and 41% in SMOFlipid® group, p=.88) or ROP requiring treatment (4% and 10%, respectively, p=.152). Weekly weight gain was similar in the 2 groups.

Conclusions: This study showed no difference between the 2 groups regarding ROP, ROP requiring treatment, or weekly weight gain in the first 6 weeks of life.

Keywords: Docosahexaenoic acid; Emulsión lipídica intravenosa; Intravenous fat emulsion; Nutrición parenteral; Omega-3 fatty acids; Parenteral nutrition; Retinopathy of prematurity; Retinopatía de la prematuridad; Ácido docosahexanoico; Ácido graso omega-3.